The Indian
heparin market is projected to reach USD 883.0 Million by 2022 from USD
381.8 Million in 2016, at a CAGR of 15.0%. Increasing prevalence of chronic
diseases such as cancer and diabetes and favorable government policies for the
pharmaceutical sector are the major factors driving the growth of Indian
peptide market.
The Indian anticoagulant drugs market to reach USD 170.2
Million in 2022 from USD 127.8 Million in 2016 and is expected to register a
CAGR of 4.9%. Factors such as incidence of coagulation disorders and government
support for pharmaceutical companies are contributing to the growth of this
market.
By type, hormonal segment is expected to dominate the market
in 2016
On the basis of type segmentation, The Indian peptide drugs
market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and
others. The hormonal segment is expected to dominate the Indian peptide drugs
market in 2016. Growing incidence and prevalence rate of diabetes in India and
rising ageing population are the major driving factors for this segment.
Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
By application, the diabetes segment is expected to dominate
the market in 2016
Based on application, the indian peptide drugs market is
segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis,
gynecological application, and other applications. In 2016, the diabetes
segment is expected to account for the largest share of the Indian peptide
drugs market, by application. The growth in the segment can be primarily
attributed to increasing incidence and prevalence of diabetes cases in the
country.
Some of the major players operating in the Indian peptide
drugs market include Abbott Laboratories (US), Sanofi S.A. (France), Eli Lilly
and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas
Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India),
Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals
Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories
Limited (India), and Alkem Laboratories Limited (India).
By type, Enoxaparin sodiumsegment is expected to dominate the
market in 2016
On the basis of Low molecular weight heparin type, the Indian
anticoagulant drugs market is classified into enoxaparin sodium, heparin
sodium, fondaparinux, and dalteparin sodium. In 2016, the enoxaparin sodium segment
is expected to account for the largest share of the Indian anticoagulant drugs
market, by type.
Enoxaparin sodium is available as an injectable that helps
prevent blood clots in the leg veins of patients who have undergone hip/knee
replacements or abdominal surgery. According to Human Pharmaceuticals at
Boehringer Ingelheim, in India, approximately 231,132 venous thromboembolism
(VTE) procedures occur annually; 53.6% of hospitalized Indian patients are at
an increased risk of VTE.
Get the Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=77044734
Some of the major players operating in the Indian
anticoagulant drugs market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd.
(India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott
Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India),
Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris
Lifesciences Limited (India), Gland Pharma Limited (India), Mylan
Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd.
(India), and VHB Lifesciences (India).
View Complete Press Release @ https://www.marketsandmarkets.com/PressReleases/indian-peptides-heparin.asp